Drug Trial Radar · NCT06191744
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,095
Actual
Start
Feb 5, 2024
Primary completion
Nov 2037
Study completion Nov 2037
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Jan 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants with previously untreated FL will be enrolled in approximately 250 sites across the world. Participants will receive R2 (intravenous \[IV\] infusion of rituximab (R) and oral capsules of lenalidomide) alone or in combination with subcutaneous injections of epcoritamab. Participants may also receive investigator's choice chemoimmunotherapy (CIT): IV infusion of obinutuzumab (G) and IV injections of cyclophosphamide, IV injections of doxorubicin, IV injections of vincristine, oral tablets of prednisone (CHOP) \[G-CHOP\]/ R-CHOP or G and IV infusion of bendamustine (Benda) \[G-Benda\]/R-Benda. The total treatment duration will be 120 weeks for all arms except A2, which is 24 weeks of treatment. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Follicular Lymphoma (FL)
Interventions
EpcoritamabDrug
Subcutaneous (SC) Injection
PrednisoneDrug
Oral Tablet
RituximabDrug
Intravenous (IV) Infusion
LenalidomideDrug
Oral Capsule
DoxorubicinDrug
IV Injection
VincristineDrug
IV Injection
CyclophosphamideDrug
IV Injection
ObinutuzumabDrug
IV Infusion
BendamustineDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30)Time frame: Up to 30 Months
- Arm A1 vs Arm B: Number of Participants with Progression-free survival (PFS)Time frame: Up to 10 Years
Locations
266 sites in 32 countries. Site status is shown where the registry gives one.
UCSF Fresno /ID# 264712
Fresno, California
Scripps Mercy Hospital /ID# 265393
San Diego, California
Sansum Clinic Research /ID# 261596
Santa Barbara, California
Rocky Mountain Cancer Centers - Boulder /ID# 261203
Boulder, Colorado
Christiana Care Health Service /ID# 261207
Newark, Delaware
Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 262445
Jacksonville, Florida
Advent Health /ID# 261578
Orlando, Florida
Orlando Health Cancer Institute /ID# 260983
Orlando, Florida
Moffitt Cancer Center /ID# 259487
Tampa, Florida
Beacon Cancer Care - Coeur d'Alene /ID# 260670
Coeur d'Alene, Idaho
Northwestern Medicine - Northwestern Memorial Hospital /ID# 259814
Chicago, Illinois
Cancer Care Specialists Of Central Illinois /ID# 272464
Decatur, Illinois
Loyola University /ID# 259462
Maywood, Illinois
Illinois Cancer Care, PC /ID# 261526
Peoria, Illinois
Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583
Fort Wayne, Indiana
University of Iowa Health Care /ID# 262132
Des Moines, Iowa
University of Louisville Hospital /ID# 260544
Louisville, Kentucky
Norton Cancer Institute - St. Matthews /ID# 261076
Louisville, Kentucky
New England Cancer Specialists - Westbrook /ID# 260672
Westbrook, Maine
University of Maryland, Baltimore /ID# 259538
Baltimore, Maryland
Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 259476
Bethesda, Maryland
St. Luke's Hospital - Chesterfield /ID# 260489
Chesterfield, Missouri
Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 260006
Billings, Montana
Nebraska Cancer Specialists (NCS) - Regional Cancer Center - St Francis Location /ID# 262506
Grand Island, Nebraska
Nebraska Hematology-Oncology /ID# 269692
Lincoln, Nebraska
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 262505
Omaha, Nebraska
University of Nebraska Medical Center /ID# 261996
Omaha, Nebraska
University of New Mexico /ID# 261083
Albuquerque, New Mexico
Presbyterian Kaseman Hospital /ID# 262451
Albuquerque, New Mexico
Presbyterian Rust Medical Center /ID# 262447
Rio Rancho, New Mexico
New York Oncology Hematology - Albany Cancer Center /ID# 261814
Albany, New York
NYU Langone Hospital - Long Island /ID# 265531
Mineola, New York
NYU Langone Medical Center /ID# 264518
New York, New York
Icahn School of Medicine at Mount Sinai /ID# 259595
New York, New York
New York Oncology Hematology /ID# 270208
Troy, New York
Clinical Research Alliance - Westbury /ID# 261078
Westbury, New York
Novant Health Presbyterian Medical Center /ID# 259740
Charlotte, North Carolina
Novant Health Forsyth Medical Center /ID# 259741
Winston-Salem, North Carolina
Oncology Hematology Care, Inc - Blue Ash /ID# 261204
Cincinnati, Ohio
Taylor Cancer Research Center /ID# 260488
Maumee, Ohio
Showing 40 of 266 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.